Feasibility of myocardial PET imaging using a benzylguanidine analog: meta-(3-[18F]fluoropropyl)benzylguanidine ([18F]mFPBG)

Sang Keun Woo, Byung Seok Moon, Bom Sahn Kim, Min Hwan Kim, Yong Jin Lee, Jae Ho Jung, Kyo Chul Lee, Youngho Seo, Wook Kim, Sang Moo Lim, Byung Chul Lee, Sang Eun Kim

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Introduction: Global and regional sympathetic activity in the heart can be evaluated using [123I]meta-iodobenzylguanidine ([123I]mIBG) imaging. However, [123I]mIBG is associated with low image spatial resolution and sensitivity in cardiac imaging. We investigated the capability of an F-18-labeled mIBG derivative, meta-(3-[18F]fluoropropyl)benzylguanidine ([18F]mFPBG), for identifying ischemic and viable myocardium in a rat model of myocardial infarction. Materials and methods: The ex vivo biodistribution and in vivo metabolic stability of [18F]mFPBG were investigated in Sprague–Dawley rats. Selective cardiac adrenergic activation was confirmed via a blocking experiment involving pretreatment with desipramine (2 mg kg−1), followed by the administration of [18F]mFPBG. Imaging properties of [18F]mFPBG were compared with those of traditional cardiac imaging radiotracers ([123I]mIBG and [99mTc]MIBI) in a rat model of myocardial infarction. Non-invasive image-based measurements of infarct sizes were then compared with histological findings by using Bland–Altman analysis. Results: The differences in infarct sizes determined using histological analysis and [18F]mFPBG PET were −2.55 ± 4.99% (range: −12.33 to 7.22), −2.35 ± 3.32% (range: −8.87 to 4.16), and −3.15 ± 6.16% (range: −15.24 to 8.93) at 5, 20, and 40 min, respectively. Furthermore, [18F]mFPBG PET was superior to traditional imaging methods in assessing the degree of ischemia in areas of myocardial infarction, as well as the actual infarct size. Conclusion: Compared to [123I]mIBG, [18F]mFPBG showed improved spatial resolution and sensitivity in a rat model of myocardial infarction. This result suggested that [18F]mFPBG is a promising cardiac PET imaging agent for potential diagnostic application in PET cardiology.

Original languageEnglish
Pages (from-to)63-70
Number of pages8
JournalNuclear Medicine and Biology
Volume61
DOIs
StatePublished - Jun 2018

Bibliographical note

Funding Information:
This study was supported by the Health Technology R&D Project through Korea Health Industry Development Institute (KHIDI) grants ( HI14C1072 and HI16C0947 ) funded by the Ministry of Health & Welfare (MOHW) of the Korean Government , and National R&D Program through the Korea Institute of Radiological and Medical Sciences funded by the Ministry of Science, ICT & Future Planning (No. 1711045543 , 1711045539 ).

Publisher Copyright:
© 2018 Elsevier Inc.

Keywords

  • F
  • Cardiac sympathetic innervation
  • Guanidine
  • Myocardial infarction
  • PET

Fingerprint

Dive into the research topics of 'Feasibility of myocardial PET imaging using a benzylguanidine analog: meta-(3-[18F]fluoropropyl)benzylguanidine ([18F]mFPBG)'. Together they form a unique fingerprint.

Cite this